Page 34 - Recent Highlights News Today : Breaking News, Live Updates & Top Stories | Vimarsana

$46,020 Gross Margin was 74% during the first quarter of 2021, as compared to 83% in the first quarter of 2020. The compression in gross margin for the first quarter of 2021 was driven by revenue mix including the launch of TREAKISYM product sales to our partner in the first quarter of 2021, on which we earn no profit. R&D expense was $14.3 million for the first quarter of 2021, compared to $9.4 million in the first quarter of 2020. The increase is largely attributable to $2.6 million in development costs for vasopressin, a $0.9 million increase in the cost for fulvestrant, and a $0.9 million...

Avinger Reports First Quarter 2021 Financial Results ACCESSWIRE 13% Year-over-Year Revenue Growth Driven by Tigereye™ Commercial Launch and Pantheris SV Sales Growth REDWOOD CITY, CA / ACCESSWIRE / May 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the first quarter ended March 31, 2021. First Quarter and Recent Highlights Revenue increased 13% year-over-year to $2.6 million, reflecting co...

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r MM and ALLO-316 in advanced or metastatic clear cell renal cell carcinoma New collaboration with Cyto...

Avinger, Inc.: Avinger Reports First Quarter 2021 Financial Results 13% Year-over-Year Revenue Growth Driven by Tigereye Commercial Launch and Pantheris SV Sales Growth REDWOOD CITY, CA / ACCESSWIRE / May 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the first quarter ended March 31, 2021. First Quarter and Recent Highlights Revenue increased 13% year-over-year to $2.6 million, reflecting c...

CGX Energy Inc.: CGX Energy Announces Filing of First Quarter Financial Statements CGX Energy" or the " Company") announced today the release of its unaudited Consolidated Financial Statements for the first quarter of 2021, together with its Management, Discussion and Analysis - Quarterly Highlights (" MD&A"). These documents will be posted on the Company's website at www.cgxenergy.com and SEDAR at www.sedar.com. All values in this news release and the Company's financial disclosures are in United States dollars unless otherwise stated. Gabriel de Alba, Co-Chairman of CGX Energy, commented: "...